<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1107233856
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2012
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VALDOXAN 25MG FILM COATED TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AGOMELATINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        104.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SERVIER" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SERVIER
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SERVIER
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AX22
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Valdoxan contains the active ingredient agomelatine. It belongs to a group of medicines called antidepressants. You have been given Valdoxan to treat your depression.</p><p>Valdoxan is used in adults.</p><p>&nbsp;</p><p>Depression is a continuing disturbance of mood that interferes with everyday life. The symptoms of depression vary from one person to another, but often include deep sadness, feelings of worthlessness, loss of interest in favourite activities, sleep disturbances, feeling of being slowed down, feelings of anxiety, changes in weight.</p><p>The expected benefits of Valdoxan are to reduce and gradually remove the symptoms related to your depression.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Valdoxan</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to agomelatine or any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if your liver does not work properly (hepatic impairment).</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking fluvoxamine (another medicine used in the treatment of depression) or ciprofloxacin (an antibiotic).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>There could be some reasons why Valdoxan may not be suitable for you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking medicines known to affect the liver. Ask your doctor for advice on which medicine that is.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are obese or overweight, ask your doctor for advice.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are diabetic, ask your doctor for advice.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have increased levels of liver enzymes before treatment, your doctor will decide if Valdoxan is right for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have bipolar disorder, have experienced or if you develop manic symptoms (a period of abnormally high excitability and emotions) talk to your doctor before you start taking this medicine or before you continue with this medicine (see also under &ldquo;<em>Possible side effects</em>&rdquo; in section 4).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are suffering from dementia, your doctor will make an individual evaluation of whether it is right for you to take Valdoxan.</p><p>&nbsp;</p><p>During your treatment with Valdoxan :</p><p>&nbsp;</p><p><em>What to do to avoid potential serious liver problems</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor should have checked that your liver is working properly <strong>before starting the treatment</strong>. Some patients may get increased levels of liver enzymes in their blood during treatment with Valdoxan. &nbsp;Therefore follow-up tests should take place at the following time points:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>before initiation or</p><p>dose increase</p></td><td style="vertical-align:top"><p>around</p><p>3 weeks</p></td><td style="vertical-align:top"><p>around</p><p>6 weeks</p></td><td style="vertical-align:top"><p>around</p><p>12 weeks</p></td><td style="vertical-align:top"><p>around</p><p>24 weeks</p></td></tr><tr><td style="vertical-align:top"><p>Blood tests</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Based on the evaluation of these tests your doctor will decide whether you should receive or continue using Valdoxan (see also under &ldquo;<em>How to take Valdoxan</em>&rdquo; in section 3).</p><p><em>&nbsp;</em></p><p>&nbsp;</p><p><em>Be vigilant about signs and symptoms that your liver may not be working properly</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you</strong> <strong>observe</strong> any of these signs and symptoms of liver problems: <strong>unusual darkening of the urine, light coloured stools, yellow skin/eyes, pain in the upper right belly, unusual fatigue (especially associated with other symptoms listed above), seek urgent advice from a doctor who may advise you to </strong><strong>stop taking Valdoxan.</strong></p><p>&nbsp;</p><p>Effect of Valdoxan is not documented in patients aged 75 years and older. Valdoxan should therefore not be used in these patients.</p><p>&nbsp;</p><p><em>Thoughts of suicide and worsening of your depression</em></p><p>If you are depressed you can sometimes have thoughts of harming or killing yourself. These may be increased when first starting antidepressants, since these medicines all take time to work, usually about two weeks but sometimes longer.</p><p>&nbsp;</p><p>You may be more likely to think like this:</p><p>- if you have previously had thoughts about killing or harming yourself.</p><p>- if you are a young adult. Information from clinical trials has shown an increased risk of suicidal behaviour in young adults (aged less than 25 years) with psychiatric conditions who were being treated with an antidepressant.</p><p>If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital straight away.</p><p>&nbsp;</p><p>You may find it helpful to tell a relative or close friend that you are depressed and ask them to read this leaflet. You might ask them to tell you if they think your depression is getting worse, or if they are worried about changes in your behaviour.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Valdoxan should not be used in children and adolescents (under 18 years old).</p><p>&nbsp;</p><p><strong>Other medicines and Valdoxan</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>You should not take Valdoxan together with certain medicines (see also under &ldquo;<em>Do not take Valdoxan</em>&rdquo; in section 2): fluvoxamine (another medicine used in the treatment of depression), ciprofloxacin (an antibiotic) can modify the expected dose of agomelatine in your blood.</p><p>Make sure to tell your doctor if you are taking any of the following medicines: propranolol (a beta-blocker used in the treatment of hypertension), enoxacin (antibiotic)</p><p>&nbsp;</p><p>Make sure to tell your doctor if you are smoking more than15 cigarettes/day.</p><p>&nbsp;</p><p><strong>Valdoxan with alcohol</strong></p><p>It is not advisable to drink alcohol while you are being treated with Valdoxan.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>Breastfeeding should be discontinued if you take Valdoxan.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>You might experience dizziness or sleepiness which could affect your ability to drive or operate machines. Make sure that your reactions are normal before driving or operating machines.</p><p>&nbsp;</p><p><strong>Valdoxan contains lactose</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>&nbsp;</p><p><strong>Valdoxan contains sodium</strong></p><p>Valdoxan contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>The recommended dose of Valdoxan is one tablet (25&nbsp;mg) at bedtime. In some cases, your doctor may prescribe a higher dose (50&nbsp;mg), i.e. two tablets to be taken together at bedtime.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Valdoxan is for oral use. You should swallow your tablet with a drink of water. Valdoxan can be taken with or without food.</p><p>&nbsp;</p><p><u>Duration of treatment</u></p><p>Valdoxan starts to act on symptoms of depression in most depressed people within two weeks of starting treatment.</p><p>Your depression should be treated for a sufficient period of at least 6 months to ensure that you are free of symptoms.</p><p>Your doctor may continue to give you Valdoxan when you are feeling better to prevent your depression from returning.</p><p>&nbsp;</p><p>If you have trouble with your kidneys, your doctor will make an individual evaluation of whether it is safe for you to take Valdoxan.</p><p>&nbsp;</p><p><em>Surveillance of the liver function (see also section 2):</em></p><p>Your doctor will run laboratory tests to check that your liver is working properly before starting treatment and then periodically during treatment, usually after 3 weeks, 6 weeks, 12 weeks and 24 weeks.</p><p>If your doctor increase the dose to 50mg, laboratory tests should be performed at this initiation and then periodically during treatment, usually after 3 weeks, 6 weeks, 12 weeks and 24 weeks. Thereafter tests will be taken if the doctor finds it necessary.</p><p>You must not use Valdoxan if your liver does not work properly.</p><p>&nbsp;</p><p><em>How to switch from an antidepressant medicine (SSRI/SNRI) to Valdoxan?</em></p><p>If your doctor changes your previous antidepressant medicine from an SSRI or SNRI to Valdoxan, he/she will advise you on how you should discontinue your previous medicine when starting Valdoxan.</p><p>You may experience discontinuation symptoms related to stopping of your previous medicine for a few weeks, even if the dose of your previous antidepressant medicine is decreased gradually.</p><p>Discontinuation symptoms include: dizziness, numbness, sleep disturbances, agitation or anxiety, headaches, feeling sick, being sick and shaking. These effects are usually mild to moderate and disappear spontaneously within a few days.</p><p>If Valdoxan is initiated while tapering the dosage of the previous medicine, possible discontinuation symptoms should not be confounded with a lack of early effect of Valdoxan.</p><p>You should discuss with your doctor on the best way of stopping your previous antidepressant medicine when starting Valdoxan.</p><p>&nbsp;</p><p><strong>If you take more Valdoxan than you should</strong></p><p>If you have taken more Valdoxan than you should, or if for example a child has taken medicine by accident, contact your doctor immediately.</p><p>The experience of overdoses with Valdoxan is limited but reported symptoms include pain in the upper part of the stomach, somnolence, fatigue, agitation, anxiety, tension, dizziness, cyanosis or malaise.</p><p>&nbsp;</p><p><strong>If you forget to take Valdoxan</strong></p><p>Do not take a double dose to make up for a forgotten dose. Just carry on with the next dose at the usual time.</p><p>The calendar printed on the blister containing the tablets should help you remembering when you last took a tablet of Valdoxan.</p><p>&nbsp;</p><p><strong>If you stop taking Valdoxan </strong></p><p>Do not stop taking your medicine without the advice of your doctor even if you feel better.</p><p>&nbsp;</p><p>If you have any further questions on the use of this product, please ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Most side effects are mild or moderate. They usually occur within the first two weeks of the treatment and are usually temporary.</p><p>&nbsp;</p><p>These side effects include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Very common side effects</u> (may affect more than 1 in 10 people) : headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Common side effects (</u>may affect up to 1 in 10 people<u>)</u>: dizziness, sleepiness (somnolence), difficulty in sleeping (insomnia), feeling sick (nausea), diarrhoea, constipation, abdominal pain, back pain, tiredness, anxiety, abnormal dreams, increased levels of liver enzymes in your blood, vomiting, weight increased.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Uncommon side effects</u> (may affect up to 1 in 100 people): migraine, pins and needles in the fingers and toes (paraesthesia), blurred vision, restless legs syndrome (a disorder that is characterized by an uncontrollable urge to move the legs), ringing in the ears, excessive sweating (hyperhidrosis), eczema, pruritus, urticaria (hives), agitation, irritability, restlessness, aggressive behaviour, nightmares, mania/hypomania (see also under &ldquo;Warnings and precautions&rdquo; in section 2), suicidal thoughts or behaviour,confusion, weight decreased, muscle pain.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Rare side effects</u> (may affect up to 1 in 1,000 people): serious skin eruption (erythematous rash), face oedema (swelling) and angioedema (swelling of the face, lips, tongue and/or throat that may cause difficulty in breathing or swallowing), hepatitis,<strong> </strong>yellow coloration of the skin or the whites of the eyes (jaundice), hepatic failure*, hallucinations, inability to remain still (due to physical and mental unrest), inability to completely empty the bladder.</p><p>&nbsp;</p><p>* Few cases resulting in liver transplantation or death have been reported.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store below 30<sup>0</sup>C</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is agomelatine. Each film-coated tablet contains 25&nbsp;mg of agomelatine.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lactose monohydrate, maize starch, povidone (K30), sodium starch glycolate type A, stearic acid, magnesium stearate, colloidal anhydrous silica,hypromellose, glycerol, macrogol (6000), yellow iron oxide (E172) and titanium dioxide (E171).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; printing ink : shellac, propylene glycol and indigo carmine aluminium lake (E132)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Valdoxan 25 mg film-coated tablets (tablet) are oblong, orange-yellow with a blue imprint of ‘company logo’  on one side.


Valdoxan 25 mg film-coated tablets are available in calendar blisters. Packs contain 14, 28, 56, 84 or 98 tablets. Not all pack sizes may be marketed.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Les Laboratoires Servier</p><p>50, rue Carnot</p><p>92284 Suresnes cedex - France</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Servier (Ireland) Industries Ltd</p><p>Gorey road</p><p>Arklow &ndash; Co. Wicklow &ndash; Ireland</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.<br />Saudi Arabia</p><p>Les Laboratoires Servier Scientific Office<br />Al-Sulaimaniah, Al-Safwah building<br />Riyadh, Saudi Arabia.<br />Tel: +966 (11) 2886813<br />E-mail: fawaz.al-anazi@servier.com</p><p>Gulf Countries<br />Les Laboratoires Servier Scientific Office<br />P.O. Box 1586, 8/F API World Tower<br />Sheikh Zayed Road, Dubai, UAE<br />Tel: +971 4 3329903<br />E-mail: magdy.abdou@servier.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in: 05.2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي فالدوكسان على المادة الفعالة أغوميلاتين التابعة لصنف الأدوية المسمّاة بمضادات الاكتئاب. لقد وُصف لك فالدوكسان لعلاج وضعك الاكتئابي.</p><p dir="RTL">يستعمل فالدوكسان لعلاج البالغين.</p><p dir="RTL">يُشكل الاكتئاب اضطراباً متواصلاً في المزاج يتدخل في الحياة اليومية. وتختلف أعراض الاكتئاب من شخص لآخر، لكنها تتضمن غالباً حزناً عميقاً وشعوراً بقلّة الأهمية وفقداناً للاهتمام بالنشاطات المفضّلة واضطرابات في النوم وشعوراً بقلة النشاط والقلق وتغييرات في الوزن.</p><p dir="RTL">إن الفائدة المتوقعة من فالدوكسان هي تخفيف الأعراض ذات الصلة بالاكتئاب والتخلص منها بالتدريج.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول فالدوكسان</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعاني من الحساسية من مادة الأغوميلاتين أو أيٍّ من المكوّنات الأخرى لهذا الدواء (المذكورة في القسم ٦).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعاني من اضطرابات كبديّة (قصور كبدي).</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تتعالج بواسطة فلوفوكسامين fluvoxamine (دواء آخر يستخدم في علاج الاكتئاب) أو بواسطة سيبروفلوكساسين ciprofloxacin (مضاد حيوي).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">هناك عدة أسباب قد تجعل من فالدوكسان دواءً غير صالح لك:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تأخذ أدوية معروفة بتأثيرها على الكبد. عليك أن تستشير الطبيب بخصوص الأدوية التي تأخذها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابا بالسمنة أو لديك زيادة في الوزن. عليك أن تستشير الطبيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بداء السكري. عليك أن تستشير الطبيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كانت مقاييس الانزيمات الكبدية مرتفعة لديك قبل المباشرة بالعلاج، فإن طبيبك هو الذي يقرّر فيما إذا كان فالدوكسان يصلح لك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تشكو من اضطراب المزاج ثنائي القطب، أو إن حصل لك بعض أعراض الهوس (فترة من التوتر العالي والانفعالات غير الطبيعية)، أعلم طبيبك &nbsp;بهذا قبل أخذ هذا الدواء أو قبل مواصلة المداواة به (راجع أيضا &quot;الآثار الجانبية المتوقعة&quot; في القسم ٤).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تشكو من الخرف، فإن طبيبك هو الذي يقدّر مدى صلاحيّة العلاج بواسطة فالدوكسان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أثناء العلاج بواسطة فالدوكسان:</p><p dir="RTL">&nbsp;</p><p dir="RTL">ما الذي يجب أن تفعله لتتجنب المشاكل الكبدية الخطيرة الممكنة الحدوث:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن يكون طبيبك قد تأكد أن كبدك يعمل بطريقة جيدة قبل البدء بالعلاج. قد يطرأ لدى بعض الأشخاص ارتفاع في مقاييس الخمائر الكبديّة في الدم خلال المداواة بواسطة فالدوكسان. لذا يجب إجراء فحوص المتابعة في الأوقات التالية:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">قبل البدء بالعلاج أو زيادة الجرعة</p></td><td style="vertical-align:top"><p dir="RTL">حوالي</p><p dir="RTL">&nbsp;3 أسابيع</p></td><td style="vertical-align:top"><p dir="RTL">حوالي</p><p dir="RTL">&nbsp;6 أسابيع</p></td><td style="vertical-align:top"><p dir="RTL">حوالي</p><p dir="RTL">&nbsp;12 أسبوعا</p></td><td style="vertical-align:top"><p dir="RTL">حوالي</p><p dir="RTL">&nbsp;24 أسبوعا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">فحوص الدم</p></td><td style="vertical-align:top"><p dir="RTL"><strong>&uuml;</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>&uuml;</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>&uuml;</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>&uuml;</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>&uuml;</strong></p></td></tr></tbody></table><p dir="RTL">استناداً لنتائج هذه التحاليل، سيقرر طبيبك إمكانيّة استعمال أو مواصلة العلاج بواسطة فالدوكسان (انظر أيضاً إلى &quot;كيف تتناول فالدوكسان&quot; في القسم ٣)</p><p dir="RTL">&nbsp;</p><p dir="RTL">كن متيقظا حيال العلامات والأعراض التي تشير إلى أن كبدك ربما لا يعمل بالطريقة المناسبة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لاحظت أيا من علامات وأعراض المشكلات الكبدية التالية: تحول لون البول إلى لون داكن خلافا للمعتاد، إذا أصبح البراز فاتح اللون، اصفرار الجلد/العينين، ألم في القسم العلوي الأيمن من البطن، تعب غير اعتيادي (وخاصة إذا ترافق مع الأعراض الأخرى المذكورة أعلاه)، فاطلب على الفور استشارة طبيب قد ينصحك بالتوقف عن تناول فالدوكسان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تأثير فالدوكسان غير موثّق لدى المرضى الذين بلغوا سنّ الخامسة والسبعين وما فوق. لذا يجب عدم استعمال فالدوكسان لدى هؤلاء المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الميول الانتحاريّة وتفاقم الاكتئاب</p><p dir="RTL">في بعض الأوضاع، من الممكن أن تتضمن أعراض الاكتئاب أفكاراً أو تصرفات تدفع للانتحار أو لإيذاء النفس. وقد تزداد تلك الأعراض في بادئ العلاج إلى أن يبدأ مفعول الدواء المضاد للاكتئاب بالتأثير بشكل تام. وهذا قد يتطلّب عادة أسبوعين أو أكثر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">فمن الممكن أنك قد أحسست بهذا في الأوضاع التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال سبق وظهرت لك ميول للانتحار أو لإيذاء النفس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت شاباً في سن البلوغ. فإن المعلومات الناتجة عن الاختبارات السريريّة أظهرت أن خطر التعرّض إلى الميول الإنتحاريّة يزداد لدى الشبّان البالغين (دون الخامسة والعشرين سنة من العمر) ممن يشكون من اضطرابات نفسيّة والمتداوون بواسطة مضادات الاكتئاب.</p><p dir="RTL">&nbsp;فإن أحسست في أي وقت من الأوقات بميول للانتحار أو لإيذاء نفسك، اتّصل فوراً بالطبيب أو توجّه حالاً إلى أقرب مستشفى.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p>ومن المستحسن إعلام أحد أقاربك أو أحد أصدقائك بوضعك الاكتئابي والطلب منهم قراءة هذه النشرة. كما يمكنك أن تطلب منهم بأن يزيدوك علماً إن كان وضعك الاكتئابي في حال تدهور أو إن كانت تقلّبات مزاجك توحي لهم بالقلق.</p><p>&nbsp;</p><p><strong>الأطفال والمراهقون</strong></p><p dir="RTL">يجب الامتناع عن استعمال فالدوكسان للأطفال أو للمراهقين (دون الثامنة عشرة سنة من العمر).</p><p>&nbsp;</p><p><strong>الأدوية الأخرى وفالدوكسان</strong></p><p dir="RTL">يجب أن تبلغ الطبيب أو الصيدلاني إن كنت تأخذ أو إن كنت قد أخذت مؤخّراً أو ربما ستتناول أي نوع من الأدوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يجوز أخذ فالدوكسان مصطحباً مع بعض أنواع الأدوية (انظر أيضاً إلى &quot;لا تتناول فالدوكسان&quot; في القسم ٢)، مثل: فلوفوكسامين fluvoxamine (نوع آخر من الأدوية المستعملة في علاج الاكتئاب)، أو سيبروفلوكساسين ciprofloxacin (مضاد حيوي) يمكنه أن يعدّل الجرعة المتوقعة من أغوميلاتين في دمك.</p><p dir="RTL">كن حريصا على إبلاغ طبيبك إذا كنت تتناول أيُّا من الأدوية التالية: بروبرانولول Propranolol (حاصر بيتا يستعمل في علاج ارتفاع ضغط الدم)، إينوكساسين enoxacine (مضاد حيوي) .</p><p dir="RTL">&nbsp;</p><p dir="RTL">احرص على إبلاغ طبيبك إذا كنت تدخن أكثر من ١٥ سيجارة يوميا.</p><p dir="RTL"><strong>فالدوكسان مع الكحول </strong></p><p dir="RTL">عليك بتجنّب شرب الكحول خلال فترة العلاج بواسطة فالدوكسان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع</strong></p><p dir="RTL">إذا كنتِ حاملا أو مرضعا، أو تعتقدين أنك ربما كنت حاملا، أو تخططين للحمل، فاطلبي نصيحة</p><p dir="RTL">طبيبك أو الصيدلاني قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوجّب التوقف عن الإرضاع &lsquo;ذا كمت تتناولين فالدوكسان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة السيّارات واستعمال الآليات</strong></p><p dir="RTL">قد تشعر بالدوار أو النعاس فتؤثر على قدرتك على قيادة المركبات أو العمل على الآلات. عليك أن تتأكد من صحة ردود أفعالك قبل القيام بقيادة السيارات أو تشغيل الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي فالدوكسان على سكر الحليب.</p><p dir="RTL">فإن كان طبيبك قد أعلمك بعدم تحملك لبعض أنواع السكاكر، عليك الاتصال بطبيبك قبل المباشرة بتناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي فالدوكسان على الصوديوم</p><p dir="RTL">يحتوي فالدوكسان على أقل من ملغم ١ ممول من الصوديوم (٢٣ ملغ) في كل حبة، ولذا يمكن اعتباره &rsquo;خاليا من الملح&lsquo;.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عليك بأخذ هذا الدواء في الموعد الذي حدّده لك الطبيب أو الصيدلاني. وإن شككت بالأمر عليك بالرجوع إلى الطبيب أو الصيدلاني.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن الجرعة الموصى بها من فالدوكسان عبارة عن حبّة واحدة (أي ٢٥ ملغ فقط) تؤخذ قبل موعد النوم. وبإمكان طبيبك في بعض الأوضاع أن يرفع مقدار الجرعة إلى حبّتين (أي ٥٠ ملغ) تؤخذان في آن واحد قبل النوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">طريقة الإعطاء</p><p dir="RTL">يؤخذ فالدوكسان عن طريق الفم. تُبتلع الحبّة مع كأس من الماء. يؤخذ فالدوكسان سواء وقت وجبات الطعام أو خارجها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">مدة العلاج</p><p dir="RTL">يبدأ فالدوكسان بإعطاء كامل مفعوله لدى معظم الأشخاص المصابين بالاكتئاب، بعد حوالي أسبوعين من العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب علاج الاكتئاب الذي تعاني منه لفترة كافية لا تقلّ عن ستة أشهر للتأكد من زوال الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يجوز التوقف عن العلاج دون مشورة الطبيب أو مزوّد الرعاية الصحية، قد يواصل طبيبك وصف فالدوكسان عندما تشعر بالتحسّن لمنع عودة أعراض الاكتئاب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من اضطرابات في كليتيك، فسيجري طبيبك تقييما فرديا لتحديد سلامة تناولك لـ فالدوكسان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">مراقبة وظائف الكبد (انظر أيضاً القسم ٢):</p><p dir="RTL">سيطلب منك طبيبك إجراء تحاليل مخبريّة ليتأكّد من حسن عمل الكبد قبل بدء العلاج، ثم إعادتها بصورة دوريّة في أثناء العلاج، عادة بعد ٣ أسابيع، ٦ أسابيع، ١٢ أسبوعا، ٢٤ أسبوعا.</p><p dir="RTL">إذا رفع الطبيب مقدار الجرعة التي تتناولها إلى ٥٠ ملغ فيجب إجراء هذه التحاليل المخبرية عند بدء هذه الجرعة ثم بصورة دورية أثناء العلاج بعد ذلك بعد ٣ أسابيع، ٦ أسابيع، ١٢ أسبوعا، ٢٤ أسبوعا. بعدئذٍ يتم إجراء التحاليل إذا وجد طبيبك أنها ضرورية.</p><p dir="RTL">يجب الامتناع عن استعمال فالدوكسان إذا كان الكبد لا يعمل بصورة طبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">كيف تنتقل من دواء مضاد للاكتئاب (من مثبطات استرداد السيروتونين الانتقائية SSRI) أو مثبطات استرداد السيروتونين والنورإبنفرين الانتقائية SNRI) إلى فالدوكسان؟</p><p dir="RTL">إذا غيّر طبيبك الدواء المضاد للاكتئاب الذي كنت تتناوله سابقا من أحد مثبطات استرداد السيروتونين الانتقائية أو أحد مثبطات استرداد السيروتونين والنورإبنفرين الانتقائية إلى فالدوكسان، فسيخبرك/تخبرك بطريقة التوقف عن تناول دوائك السابق عند البدء بتناول فالدوكسان.</p><p dir="RTL">قد تعاني من أعراض الإيقاف ذات الصلة بدوائك السابق لعدة أسابيع، حتى ولو تم إنقاص جرعة الدواء المضاد للاكتئاب الذي كنت تتناوله سابقا بالتدريج.</p><p dir="RTL">تشمل أعراض الإيقاف: الدوخة، التنميل، اضطراب النوم، الهياج أو القلق، حالات الصداع، الشعور بالغثيان، التقيؤ والرجفان. هذه التأثيرات تكون خفيفة إلى متوسطة الشدة عادة وتختفي لوحدها خلال بضعة أيام.</p><p dir="RTL">إذا تم البدء بإعطاء فالدوكسان أثناء تخفيض جرعة الدواء السابق، فيجب عدم الخلط بين أعراض الإيقاف الممكنة الحدوث وغياب التأثير المبكر لفالدوكسان.</p><p dir="RTL">يجب أن تناقش مع طبيبك أفضل طرق إيقاف الدواء المضاد للاكتئاب الذي كنت تتناوله سابقا عند البدء بتناول فالدوكسان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت جرعة أكبر مما يجب من</strong> <strong>فالدوكسان</strong></p><p dir="RTL">إن طرأ وأخذت فالدوكسان بجرعة تفوق تلك التي وصفها لك الطبيب، أو إن حدث وتناول الدواء طفل بصورة عفويّة، اتّصل بالطبيب فوراً.</p><p dir="RTL">وقد سجّلت بنسب محدودة أعراض الإفراط بالجرعة ولوحظ بأنها تسبّب ألماً في أعلى المعدة، نعاس، تعب، اضطراب، قلق، توتر، دوّار، زراق أو وعكة.</p><p>&nbsp;</p><p><strong>إذا نسيت</strong><strong> تناول فالدوكسان</strong></p><p>لا يجوز على الإطلاق مضاعفة الجرعة نتيجة السهو. عليك تناول الجرعة اللاحقة في موعدها المحدد.</p><p>إن التقويم المطبوع على الصفيحة الحاوية للحبّات يذكرك بآخر موعد أخذت فيه حبّة فالدوكسان.</p><p>&nbsp;</p><p><strong>&nbsp;إذا توقفت عن تناول فالدوكسان</strong></p><p>لا تتوقف عن تناول هذا الدواء دون نصيحة طبيبك حتى وإن شعرت بتحسّن.</p><p>&nbsp;</p><p>إن كان لديك المزيد من الأسئلة عن كيفيّة استعمال هذا الدواء، فاسأل الطبيب أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع كافة الأدوية، فقد تظهر مع هذا الدواء، بعض الأعراض المزعجة، رغم أنها لا تخص كافة الأشخاص.</p><p dir="RTL">تكون معظم الآثار الجانبية خفيفة، أو معتدلة، وتظهر عادة خلال الأسبوعين الأولين من العلاج، وتكون مؤقتة في معظم الأحيان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;وتشمل الآثار الجانبيّة على ما يلي:</p><p dir="RTL">-&nbsp; &nbsp;&nbsp;&nbsp;<u>الآثار الجانبيّة الشائعة جدا</u><u> </u>(قد تصيب أكثر من ١ من ١٠ أفراد): صداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>الآثار الجانبيّة الشائعة</u><u> </u>(قد تصيب حتى ١ من ١٠ أفراد): دوخة، نُعاس، صعوبة في النوم (أرق)، الإحساس بالوعكة (غثيان)، إسهال، إمساك، آلام بطنيّة، ألم في الظهر، إرهاق، قلق، أحلام غير طبيعية، ارتفاع مقاييس الخمائر الكبدية في الدم، قيء، زيادة الوزن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>الآثار الجانبيّة غير الشائعة </u>(قد تصيب حتى ١ من ١٠٠ فرد): شقيقة، شعور كوخز الإبر والدبابيس في أصابع الأيدي والأرجل، اضطرابات بصرية، متلازمة تململ الساقين (اضطراب يتصف برغبة لا يمكن السيطرة عليها لتحريك الساقين)، طنين في الأذنين، تعرّق زائد، إكزيمة، حكة، شرى، تهيج، سرعة الإنفعال تململ، سلوك عدواني، كوابيس،. هوس / هوس خفيف (راجع أيضا &quot;تحذيرات واحتياطات&quot; في القسم ٢)، لأفكار أو تصرفات انتحارية، ارتباك، نقصان الوزن، آلام عضلية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>الآثار الجانبيّة النادرة</u> (قد تصيب حتى ١ من ١٠٠٠ فرد) تهيّج جلدي شديد (طفح حُمامي)، تورم الوجه (انتفاخ) والوذمة الوعائية (تورم الوجه، الشفتين، اللسان، و/أو الحنجرة مما قد يسبب صعوبة التنفس أو البلع)، التهاب كبدي، تلون الجلد أو بياض العينين باللون الأصفر (يرقان)، فشل كبدي*، هلوسات، عدم القدرة على البقاء دون حركة (نتيجة لعددم ارتياح جسدي أو ذهني)، عدم القدرة على إفراغ البول بشكل كامل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">* تم الإبلاغ عن عدد قليل من الحالات التي أدت إلى زرع الكبد أو الوفاة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن التأثيرات الجانبية</strong></p><p dir="RTL">إذا أصبت بأي آثار جانبية، تحدث إلى طبيبك أو الصيدلاني. هذا يشمل أي آثار جانبية ممكنة حتى ولو لم يرد ذكرها في هذه النشرة. يمكنك أيضا الإبلاغ عن التأثيرات الجانبية مباشرة عن طريق نظام الإبلاغ الوطني المشار إليه في القسم ٦. عند إبلاغك عن الآثار الجانبية فأنت تساعد بتقديم مزيد من المعلومات عن سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;احتقظ بهذا الدواء بعيدا عن مرأى الأطفال ومتناول أيديهم.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p>لا تستعمل هذا الدواء بعد مرور تاريخ انتهاء الفعالية المذكور على العلبة وعلى الصفيحة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p>&nbsp;</p><p>لا يتطلب هذا الدواء شروطا خاصة لحفظه</p><p>&nbsp;</p><p dir="RTL">لا تتخلص من أي دواء في مياه المجاري العامة أو مع قمامة المنزل. اسأل الصيدلاني عن طريقة التخلص من الأدوية التي لم تعد تستعملها. هذه الإجراءات تساعد على حماية البيئة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- المادة الفعّالة هي الأغوميلاتين، كل حبّة ملبّسة تحتوي على ٢٥ ملغ من الأغوميلاتين.</p><p dir="RTL">- المركّبات الأخرى هي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سكر الحليب أحادي الماء، نشاء الذرة، بوفيدون (K30)، غليكولات نشاء الصوديوم نوع أ، حمض دهني، ستيارات المغنيزيوم، سيليكا غروانيّة لامائيّة هيبروملوز، غليسيرول، ماكروغول ٦٠٠٠٠، أوكسيد الحديد الأصفر (E172)، ثاني أوكسيد التيتانيوم (E171).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صبغة الطباعة: طلاء راتنجي، غليكول البروبيلين وإنديغو كارمين صبغة الألمنيوم (E132).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">إن فالدوكسان ٢٥ ملغ حبّات (حبّة) ملبّسة عبارة عن حبّات صفراء برتقاليّة اللون، متطاولة الشكل، طبعت بالأزرق على وجه منها رمز الشركة <!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Image_x0020_3" o:spid="_x0000_i1025" type="#_x0000_t75"
 alt="Description&nbsp;: Nouveau LOGO_SERVIER_CP_VALDOXAN" style='width:33pt;
 height:14.25pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/MDOI_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title="Nouveau LOGO_SERVIER_CP_VALDOXAN"/>
</v:shape><![endif]--><img width="44" height="19" alt="Description : Nouveau LOGO_SERVIER_CP_VALDOXAN" src="file:///C:/Users/MDOI_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />.</p><p dir="RTL" style="text-align:right">تتوفر فالدوكسان ٢٥ ملغ حبّات ملبّسة&shy; في صفيحات طُبع عليها تقويم.</p><p dir="RTL" style="text-align:right">تحتوي العبوة على ١٤، ٢٨، ٥٦، ٨٤ أو ٩٨ حبّة. كما تتوفر عبوات تحتوي على ١٠٠ حبّة لاستعمال المشافي.</p><p dir="RTL" style="text-align:right">قد لا يتم تسويق كافة حجوم العبوات.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>ج. صاحب إجازة التسويق<br />مختبرات سيرفييه<br />Les Laboratoires Servier<br />50, rue Carnot<br />92284 Suresnes cedex - France</p><p>&nbsp;</p><p><strong>الجهة المصنعة</strong></p><p>سيرفيه (إيرلندا) للتصنيع المحدودة</p><p>Servier (Ireland) Industries Ltd<br />Gorey Road<br />Arklow - Co. Wicklow &ndash; Ireland</p><p>&nbsp;</p><p>للحصول على أي معلومات تتعلق بهذا الدواء، الرجاء الاتصال بالوكيل المحلي للجهة الحاملة<br />لإجازة التسويق.</p><p>المملكة العربية السعودية<br />المكتب العلمي لمختبرات سيرفييه<br />السليمانية، بناء الصفوة<br />الرياض، المملكة العربية السعودية<br />هاتف: +٦٦٦١١٢٢٢٦٢١٣<br />البريد الالكتروني</p><p>fawaz.al-anazi@servier.com</p><p>بلدان الخليج<br />المكتب العلمي لمختبرات سيرفييه<br />ص.ب. ١٥٢٦ ، الطابق الثامن أبراج API العالمية،<br />طريق الشيخ زايد، دبي، الإمارات العربية المتحدة<br />+ هاتف: ٦٧١٤٣٣٢٦٦٥٣<br />البريد الالكتروني:<br />magdy.abdou@ae.servier.com</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت المراجعة الأخيرة لهذه النشرة في 05– 2020.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Valdoxan 25 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 25 mg of agomelatine.

Excipient with known effect

Each film-coated tablet contains 61.8 mg lactose (as monohydrate) 

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).
Orange-yellow, oblong, 9.5 mm long, 5.1 mm wide film-coated tablet with blue imprint of company logo on one side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Valdoxan is indicated for the treatment of major depressive episodes in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>The recommended dose is 25&nbsp;mg once daily taken orally at bedtime.</p><p>After two weeks of treatment, if there is no improvement of symptoms, the dose may be increased to 50&nbsp;mg once daily, i.e. two 25&nbsp;mg tablets, taken together at bedtime.</p><p>&nbsp;</p><p>Decision of dose increase has to be balanced with a higher risk of transaminases elevation. Any dose increase to 50 mg should be made on an individual patient benefit/risk basis and with strict respect of Liver Function Test monitoring.</p><p>&nbsp;</p><p>Liver function tests should be performed in all patients before starting treatment. Treatment should not be initiated if transaminases exceed 3 X upper limit of normal (see sections 4.3 and 4.4).</p><p>During treatment transaminases should be monitored &nbsp;periodically after around three weeks, six weeks (end of acute phase), twelve weeks and twenty four weeks (end of maintenance phase) and thereafter when clinically indicated (see also section 4.4). Treatment should be discontinued if transaminases exceed 3 X upper limit of normal (see sections 4.3 and 4.4).</p><p>When increasing the dosage, liver function tests should again be performed at the same frequency as when initiating treatment.</p><p>&nbsp;</p><p><em>Treatment duration</em></p><p>Patients with depression should be treated for a sufficient period of at least 6 months to ensure that they are free of symptoms.</p><p>&nbsp;</p><p><em>Switching therapy from SSRI/SNRI antidepressant to agomelatine</em></p><p>Patients may experience discontinuation symptoms after cessation from an SSRI/ SNRI antidepressant.</p><p>The SmPC of the actual SSRI/SNRI should be consulted on how to withdraw the treatment to avoid this. Agomelatine can be started immediately while tapering the dosage of a SSRI//SNRI (see section 5.1).</p><p>&nbsp;</p><p><em>Treatment discontinuation</em></p><p>No dosage tapering is needed on treatment discontinuation.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly</em></p><p>The efficacy and safety of agomelatine (25 to 50mg/day) have been established in elderly depressed patients (&lt; 75years). No effect is documented &nbsp;in patients &ge;75 years. Therefore, agomelatine should not be used by patients in this age group (see sections 4.4 and 5.1). No dose adjustment is required in relation to age (see section 5.2).</p><p>&nbsp;</p><p><em>Renal impairment </em></p><p>No relevant modification in agomelatine pharmacokinetic parameters in patients with severe renal impairment has been observed. However, only limited clinical data on the use of agomelatine in depressed patients with severe or moderate renal impairment with major depressive episodes is available. Therefore, caution should be exercised when prescribing agomelatine to these patients.</p><p>&nbsp;</p><p><em>Hepatic impairment </em></p><p>Agomelatine is contraindicated in patients with hepatic impairment (see sections 4.3, 4.4 and 5.2).</p><p>&nbsp;</p><p><em>Paediatric population&nbsp;</em></p><p>The safety and efficacy of agomelatine in children from 2 years onwards for treatment of major depressive episodes have not yet been established. No data are available (see section 4.4).</p><p>There is no relevant use of agomelatine in children from birth to 2 years for treatment of major depressive episodes.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>For oral use.</p><p>Valdoxan film-coated tablets may be taken with or without food.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Hepatic impairment (i.e. cirrhosis or active liver disease) or transaminases exceeding 3 X upper limit of normal (see sections 4.2 and 4.4).
Concomitant use of potent CYP1A2 inhibitors (e.g. fluvoxamine, ciprofloxacin) (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Monitoring of liver function</u></p><p>&nbsp;</p><p>Cases of liver injury, including hepatic failure (few cases were exceptionally reported with fatal outcome or liver transplantation in patients with hepatic risk factors), elevations of liver enzymes exceeding 10 times upper limit of normal, hepatitis and jaundice have been reported in patients treated with agomelatine in the post-marketing setting (see section 4.8). Most of them occurred during the first months of treatment. The pattern of liver damage is predominantly hepatocellular with increased serum transaminases, which usually return to normal levels on cessation of agomelatine.</p><p><strong>&nbsp;</strong></p><p><strong>Caution</strong><strong> should be exercised before starting treatment and close surveillance should be performed throughout the treatment period in all patients, especially if </strong><strong>hepatic injury</strong><strong> risk factors </strong><strong>or concomitant medicinal products associated with risk of hepatic injury</strong> <strong>are present</strong>.</p><p>&nbsp;</p><p><em>Before starting treatment</em></p><p>Treatment with Valdoxan should only be prescribed after careful consideration of benefit and risk in patients with hepatic injury risk factors e.g.:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;obesity/overweight/non-alcoholic fatty liver disease, diabetes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alcohol use disorder and /or substantial alcohol intake</p><p>and in patients receiving concomitant medicinal products associated with risk of hepatic injury.</p><p>Baseline liver function tests should be undertaken in all patients and treatment should not be initiated in patients with baseline values of ALT and/or AST &gt;3 X upper limit of normal (see section 4.3). Caution should be exercised when Valdoxan is administered to patients with pretreatment elevated transaminases (&gt; the upper limit of the normal ranges and &pound;3 times the upper limit of the normal range).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><u>Frequency of liver function tests</u></em></p><p>- before starting treatment</p><p>- and then:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; after around 3 weeks,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; after around 6 weeks (end of acute phase),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; after around 12 and 24 weeks (end of maintenance phase),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and thereafter when clinically indicated.</p><p>-&nbsp;&nbsp;&nbsp; When increasing the dosage, liver function tests should again be performed at the same frequency as when initiating treatment.</p><p>&nbsp;</p><p>Any patient who develops increased serum transaminases should have his/her liver function tests repeated within 48 hours.</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>During treatment period</em></p><p>Valdoxan treatment should be discontinued immediately if:</p><p>‐&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patient develops symptoms or signs of potential liver injury (such as dark urine, light coloured stools, yellow skin/eyes, pain in the upper right belly, sustained new-onset and unexplained fatigue).</p><p>‐&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the increase in serum transaminases exceeds 3 X upper limit of normal.</p><p>&nbsp;</p><p>Following discontinuation of Valdoxan therapy liver function tests should be repeated until serum transaminases return to normal.</p><p><em>&nbsp;</em></p><p><u>Use in </u><u>paediatric population</u></p><p>&nbsp;</p><p>Valdoxan is not recommended in the treatment of depression in patients under 18 years of age since safety and efficacy of Valdoxan have not been established in this age group. In clinical trials among children and adolescents treated with other antidepressants, suicide-related behaviour (suicide attempt and suicidal thoughts), and hostility (predominantly aggression, oppositional behaviour and anger) were more frequently observed compared to those treated with placebo (see section 4.2).</p><p>&nbsp;</p><p><u>Elderly</u></p><p>No effect of agomelatine is documented in patients &ge;75 years, therefore agomelatine should not be used by patients in this age group (see also sections 4.2 and 5.1).</p><p>&nbsp;</p><p><u>Use in elderly with dementia</u></p><p>&nbsp;</p><p>Valdoxan should not be used for the treatment of major depressive episodes in elderly patients with dementia since the safety and efficacy of Valdoxan have not been established in these patients.</p><p>&nbsp;</p><p><u>Bipolar disorder/ mania / hypomania</u></p><p>&nbsp;</p><p>Valdoxan should be used with caution in patients with a history of bipolar disorder, mania or hypomania and should be discontinued if a patient develops manic symptoms (see section 4.8).</p><p>&nbsp;</p><p><u>Suicide/suicidal thoughts</u></p><p>&nbsp;</p><p>Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.</p><p>Patients with a history of suicide-related events or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebo-controlled clinical trials of antidepressants in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo, in patients less than 25 years old.</p><p>Close supervision of patients and in particular those at high risk should accompany treatment especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted to the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.</p><p>&nbsp;</p><p><u>Combination with CYP1A2&nbsp;inhibitors&nbsp;(see sections 4.3 and 4.5)</u>&nbsp;</p><p>&nbsp;</p><p>Caution should be exercised&nbsp;when prescribing Valdoxan with&nbsp;moderate CYP1A2 inhibitors (<em>e.g.</em> propranolol, enoxacin) which may result in increased exposure of agomelatine.</p><p>&nbsp;</p><p><u>Lactose intolerance</u></p><p>&nbsp;</p><p>Valdoxan contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>&nbsp;</p><p><u>Level of sodium</u></p><p>&nbsp;</p><p>Valdoxan contains less than 1 mmol sodium (23 mg) per tablet, i.e. essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Potential interactions affecting agomelatine</u></p><p>&nbsp;</p><p>Agomelatine is metabolised mainly by cytochrome P450 1A2 (CYP1A2) (90%) and by CYP2C9/19 (10%). Medicinal products that interact with these isoenzymes may decrease or increase the bioavailability of agomelatine.</p><p>Fluvoxamine, a potent CYP1A2 and moderate CYP2C9 inhibitor markedly inhibits the metabolism of agomelatine resulting in a 60-fold (range 12-412) increase of agomelatine exposure.</p><p>Consequently, co-administration of Valdoxan with potent CYP1A2 inhibitors (e.g. fluvoxamine, ciprofloxacin) is contraindicated.</p><p>Combination of agomelatine with oestrogens (moderate CYP1A2 inhibitors) results in a several fold increased exposure of agomelatine. While there was no specific safety signal in the 800 patients treated in combination with oestrogens, caution should be exercised when prescribing agomelatine with other moderate CYP1A2 inhibitors (e.g.&nbsp;propranolol, enoxacin) until more experience has been gained (see section 4.4).</p><p>Rifampicin an inducer of all three cytochromes&nbsp;involved in the metabolism of agomelatine may decrease the bioavailability of agomelatine.</p><p>Smoking induces CYP1A2 and has been shown to decrease the bioavailability of agomelatine, especially in heavy smokers (<u>&gt;</u> 15 cigarettes/day) (see section 5.2).</p><p>&nbsp;</p><p><u>Potential for agomelatine to affect other medicinal products</u></p><p><u>&nbsp;</u></p><p><em>In vivo</em>, agomelatine does not induce CYP450 isoenzymes. Agomelatine inhibits neither CYP1A2 <em>in vivo</em> nor the other CYP450 <em>in vitro</em>. Therefore, agomelatine will not modify exposure to medicinal products metabolised by CYP 450.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Other medicinal products</u></p><p>&nbsp;</p><p>No evidence of pharmacokinetic or pharmacodynamic interaction with medicinal products which could be prescribed concomitantly with Valdoxan in the target population was found in phase I clinical trials: benzodiazepines, lithium, paroxetine, fluconazole and theophylline.</p><p>&nbsp;</p><p><u>Alcohol</u></p><p>&nbsp;</p><p>The combination of agomelatine and alcohol is not advisable.</p><p>&nbsp;</p><p><u>Electroconvulsive therapy (ECT)</u></p><p>&nbsp;</p><p>There is no experience of concurrent use of agomelatine with ECT. Animal studies have not shown proconvulsant properties (see section 5.3). Therefore, clinical consequences of ECT performed concomitantly with agomelatine treatment, are considered to be unlikely.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Interaction studies have only been performed in adults.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><em>&nbsp;</em></p><p>There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of agomelatine in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). As a precautionary measure<strong>, </strong>it is preferable to avoid the use of Valdoxan during pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is not known whether agomelatine/metabolites are excreted in human milk. Available pharmacodynamic/toxicological data in animals have shown excretion of agomelatine/metabolites in milk (see section 5.3). A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Valdoxan therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.</p><p><u>&nbsp;</u></p><p><u>Fertility</u></p><p><em>&nbsp;</em></p><p>Reproduction studies in the rat and the rabbit showed no effect of agomelatine on fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Agomelatine has minor influence on the ability to drive and use machines.Considering that dizziness and somnolence are common adverse reactions, patients should be cautioned about their ability to drive or operate machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p><u>&nbsp;</u></p><p>Adverse reactions were usually mild or moderate and occurred within the first two weeks of treatment. The most common adverse reactions were headache, nausea and dizziness.</p><p>These adverse reactions were usually transient and did not generally lead to cessation of therapy.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p><u>&nbsp;</u></p><p>The below table gives the adverse reactions observed from placebo-controlled and active-controlled clinical trials.</p><p>Adverse reactions are listed below using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data). The frequencies have not been corrected for placebo.</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>System organ class</p></td><td style="vertical-align:top"><p>Frequency</p></td><td style="vertical-align:top"><p>Preferred Term</p></td></tr><tr><td rowspan="9" style="vertical-align:top"><p>Psychiatric disorders</p></td><td rowspan="2" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Anxiety</p></td></tr><tr><td style="vertical-align:top"><p>Abnormal dreams*</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Suicidal thoughts or behaviour (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Agitation and related symptoms* (such as irritability and restlessness)</p></td></tr><tr><td style="vertical-align:top"><p>Aggression*</p></td></tr><tr><td style="vertical-align:top"><p>Nightmares*</p></td></tr><tr><td style="vertical-align:top"><p>Mania/hypomania*</p><p>These symptoms may also be due to the underlying disease (see section 4.4).</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Confusional state*</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hallucinations*</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dizziness</p></td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Migraine</p></td></tr><tr><td style="vertical-align:top"><p>Paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Restless leg syndrome*</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Akathisia*</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Blurred vision</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Tinnitus*</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Gastrointestinal Disorders</p><p>&nbsp;</p></td><td rowspan="5" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting*</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Hepato- biliary disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Increased ALT and/or AST (in clinical trials, increases &gt;3 times the upper limit of the normal range for ALT and/or AST were seen in 1.2% of patients on agomelatine 25 mg daily and 2.6 % on agomelatine 50 mg daily vs. 0.5% on placebo).</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Increased gamma-glutamyltransferase* (GGT)(&gt;3 times the upper limit of the normal range</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hepatitis</p></td></tr><tr><td style="vertical-align:top"><p>Increased alkaline phosphatase*</p><p>(&gt;3 times the upper limit of the normal range)</p></td></tr><tr><td style="vertical-align:top"><p>Hepatic failure*(1)</p></td></tr><tr><td style="vertical-align:top"><p>Jaundice*</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td rowspan="4" style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hyperhidrosis</p></td></tr><tr><td style="vertical-align:top"><p>Eczema</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus*</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria*</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Erythematous rash</p></td></tr><tr><td style="vertical-align:top"><p>Face oedema and angioedema*</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Back pain</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Myalgia*</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Urinary retention*</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Fatigue</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Weight increased *</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Weight decreased*</p></td></tr></tbody></table><p>* Frequency estimated from clinical trials for adverse reactions detected from spontaneous report</p><p>(1) Few cases were exceptionally reported with fatal outcome or liver transplantation in patients with hepatic risk factors.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions </u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p><p>&nbsp;</p><p>&nbsp;</p><ul><li>Saudi Arabia</li></ul><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>- National Pharmacovigilance Center (NPC)</p><p>- Fax: +966-11-205-7662</p><p>- SFDA call Center 19999</p><p>- Toll free phone: 8002490000</p><p>- E-mail: npc.drug@sfda.gov.sa</p><p>- Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p><u>&nbsp;</u></p><p>There is limited experience with agomelatine overdose. Experience with agomelatine in overdose has indicated that epigastralgia, somnolence, fatigue, agitation, anxiety, tnsion, dizziness, cyanosis or malaise have been reported.</p><p>One person having ingested 2,450 mg agomelatine, recovered spontaneously without cardiovascular and biological abnormalities.</p><p><u>&nbsp;</u></p><p><u>Management</u></p><p><u>&nbsp;</u></p><p>No specific antidotes for agomelatine are known. Management of overdose should consist of treatment of clinical symptoms and routine monitoring. Medical follow-up in a specialised environment is recommended.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Psychoanaleptics, other antidepressants, ATC-code: N06AX22</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Agomelatine is a melatonergic agonist (MT<sub>1</sub> and MT<sub>2</sub> receptors) and 5-HT<sub>2C</sub> antagonist. Binding studies indicate that agomelatine has no effect on monoamine uptake and no affinity for a, b adrenergic, histaminergic, cholinergic, dopaminergic and benzodiazepine receptors.</p><p>Agomelatine resynchronises circadian rhythms in animal models of circadian rhythm disruption. Agomelatine increases noradrenaline and dopamine release specifically in the frontal cortex and has no influence on the extracellular levels of serotonin.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>Agomelatine has shown an antidepressant-like effect in animal models of depression (learned helplessness test, despair test, chronic mild stress) as well as in models with circadian rhythm desynchronisation and in models related to stress and anxiety.</p><p>In humans, agomelatine has positive phase shifting properties; it induces a phase advance of sleep, body temperature decline and melatonin onset.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>The efficacy and safety of agomelatine in major depressive episodes have been studied in a clinical programme including 7,900 patients treated with agomelatine.</p><p>Ten placebo controlled trials have been performed to investigate the short term efficacy of agomelatine in major depressive disorder in adults, with fixed dose and/or dose up-titration. At the end of treatment (over 6 or 8 weeks), significant efficacy of agomelatine 25-50&nbsp;mg was demonstrated in 6 out of the ten short-term double-blind placebo-controlled trials. Primary endpoint was change in HAMD-17 score from baseline. Agomelatine failed to differentiate from placebo in two trials where the active control, paroxetine or fluoxetine showed assay sensitivity. Agomelatine was not compared directly with paroxetine and fluoxetine as these comparators where added in order to ensure assay sensitivity of the trials. In two other trials, it was not possible to draw any conclusions because the active controls, paroxetine or fluoxetine, failed to differentiate from placebo. However, in these studies it was not allowed to increase the start dose of either agomelatine, paroxetine or fluoxetine even if the response was not adequate.</p><p>Efficacy was also observed in more severely depressed patients (baseline HAM-D &sup3; 25) in all positive placebo-controlled trials.</p><p>Response rates were statistically significantly higher with agomelatine compared with placebo.</p><p>Superiority (2 trials) or non-inferiority (4 trials) has been shown in six out of seven efficacy trials in heterogeneous populations of depressed adult patients versus SSRI/SNRI (sertraline, escitalopram, fluoxetine, venlafaxine or duloxetine) The anti-depressive effect was assessed with the HAMD-17 score either as primary or secondary endpoint.</p><p>The maintenance of antidepressant efficacy was demonstrated in a relapse prevention trial. Patients responding to&nbsp;8/10-weeks of acute treatment with open-label agomelatine 25-50&nbsp;mg once daily were randomised to either&nbsp;agomelatine&nbsp;25-50&nbsp;mg once daily or placebo for further 6-months. Agomelatine&nbsp;25-50&nbsp;mg once daily demonstrated a statistically significant superiority compared to placebo (p=0.0001) on the primary outcome measure, the prevention of depressive relapse, as measured by time to relapse. The incidence of relapse during the 6-months double-blind follow up period was 22% and 47% for agomelatine and placebo, respectively.</p><p>&nbsp;</p><p>Agomelatine does not alter daytime vigilance and memory in healthy volunteers. In depressed patients, treatment with agomelatine 25&nbsp;mg increased slow wave sleep without modification of REM (Rapid Eye Movement) sleep amount or REM latency. Agomelatine 25&nbsp;mg also induced an advance of the time of sleep onset and of minimum heart rate. From the first week of treatment, onset of sleep and the quality of sleep were significantly improved without daytime clumsiness as assessed by patients.</p><p>&nbsp;</p><p>In a specific sexual dysfunction comparative trial with remitted depressed patients, there was a numerical trend (not statistically significant) towards less sexual emergent dysfunction than venlafaxine for Sex Effects Scale (SEXFX) drive arousal or orgasm scores on agomelatine. The pooled analysis of trials using the Arizona Sexual Experience Scale (ASEX) showed that agomelatine was not associated with sexual dysfunction. In healthy volunteers agomelatine preserved sexual function in comparison with paroxetine.</p><p>&nbsp;</p><p>Agomelatine had neutral effect on heart rate and blood pressure in clinical trials.</p><p>&nbsp;</p><p>In a trial designed to assess discontinuation symptoms by the Discontinuation Emergent Signs and Symptoms (DESS) check-list in patients with remitted depression, agomelatine did not induce discontinuation syndrome after abrupt treatment cessation.</p><p>Agomelatine has no abuse potential as measured in healthy volunteer studies on a specific visual analogue scale or the Addiction Research Center Inventory (ARCI) 49 check-list.</p><p>A placebo-controlled 8-week trial of agomelatine 25-50mg/day in elderly depressed patients (&ge; 65 years, N=222, of which 151 on agomelatine) demonstrated a statistically significant difference of 2.67 points on HAM-D total score, the primary outcome. Responder rate analysis favoured agomelatine. No improvement was observed in very elderly patients (&ge;75 years, N= 69, of which 48 on agomelatine). Tolerability of agomelatine in elderly patients was comparable to that seen in the younger adults.</p><p>&nbsp;</p><p>A specific controlled, 3-week trial has been conducted in patients suffering from major depressive disorder and insufficiently improved with paroxetine (a SSRI) or venlafaxine (a SNRI). When treatment was switched from these antidepressants to agomelatine, discontinuation symptoms arose after cessation of the SSRI or SNRI treatment, either after abrupt cessation or gradual cessation of the previous treatment. These discontinuation symptoms may be confounded with a lack of early benefit of agomelatine.</p><p>The percentage of patients with at least one discontinuation symptom one week after the SSRI/SNRI treatment stop, was lower in the long tapering group (gradual cessation of the previous SSRI/SNRI within 2 weeks) than in the short tapering group (gradual cessation of the previous SSRI/SNRI within 1 week) and in the abrupt substitution group (abrupt cessation): 56.1%, 62.6 % and 79.8% respectively.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with agomelatine in one or more subsets of the paediatric population in the treatment of major depressive episodes (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption and bioavailability</u></p><p><em>&nbsp;</em></p><p>Agomelatine is rapidly and well (&sup3; 80%) absorbed after oral administration. Absolute bioavailability is low (&lt; 5% at the therapeutic oral dose) and the interindividual variability is substantial. The bioavailability is increased in women compared to men. The bioavailability is increased by intake of oral contraceptives and reduced by smoking. The peak plasma concentration is reached within 1 to 2 hours.</p><p>&nbsp;</p><p>In the therapeutic dose-range, agomelatine systemic exposure increases proportionally with dose. At higher doses, a saturation of the first-pass effect occurs.</p><p>Food intake (standard meal or high fat meal) does not modify the bioavailability or the absorption rate. The variability is increased with high fat food.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>Steady state volume of distribution is about 35&nbsp;l and plasma protein binding is 95% irrespective of the concentration and is not modified with age and in patients with renal impairment but the free fraction is doubled in patients with hepatic impairment.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Following oral administration, agomelatine is rapidly metabolised mainly via hepatic CYP1A2; CYP2C9 and CYP2C19 isoenzymes are also involved but with a low contribution.</p><p>The major metabolites, hydroxylated and demethylated agomelatine, are not active and are rapidly conjugated and eliminated in the urine.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Elimination is rapid, the mean plasma half-life is between 1 and 2 hours and the clearance is high (about 1,100&nbsp;ml/min) and essentially metabolic.</p><p>Excretion is mainly (80%) urinary and in the form of metabolites, whereas unchanged compound recovery in urine is negligible.</p><p>Kinetics are not modified after repeated administration.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p><em>&nbsp;</em></p><p>No relevant modification of pharmacokinetic parameters in patients with severe renal impairment has been observed (n=8, single dose of 25&nbsp;mg), but caution should be exercised in patients with severe or moderate renal impairment as only limited clinical data are available in these patients (see section 4.2).</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p><em>&nbsp;</em></p><p>In a specific study involving cirrhotic patients with chronic mild (Child-Pugh type A) or moderate (Child-Pugh type B) liver impairment, exposure to agomelatine 25&nbsp;mg was substantially increased (70-times and 140-times, respectively), compared to matched volunteers (age, weight and smoking habit) with no liver failure (see section 4.2, 4.3 and 4.4).</p><p>&nbsp;</p><p><u>Elderly</u></p><p>&nbsp;</p><p>In a pharmacokinetic study in elderly patients (&ge; 65 years), it was showed that at a dose of 25 mg the mean AUC and mean Cmax were about 4-fold and 13-fold higher for patients &ge; 75 years old compared to patients &lt; 75 years old. The total number of patients receiving 50 mg was too low to draw any conclusions. No dose adaptation is required in elderly patients.</p><p>&nbsp;</p><p><u>Ethnic groups</u></p><p><em>&nbsp;</em></p><p>There is no data on the influence of race on agomelatine pharmacokinetics.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In mice, rats and monkeys sedative effects were observed after single and repeated administration at high doses.</p><p>In rodents, a marked induction of CYP2B and a moderate induction of CYP1A and CYP3A were seen from 125&nbsp;mg/kg/day whereas in monkeys the induction was slight for CYP2B and CYP3A at 375&nbsp;mg/kg/day. No hepatotoxicity was observed in rodents and monkeys in the repeat dose toxicity studies.</p><p>Agomelatine passes into the placenta and foetuses of pregnant rats.</p><p>Reproduction studies in the rat and the rabbit showed no effect of agomelatine on fertility, embryofoetal development and pre- and post natal development.</p><p>A battery of <em>in vitro</em> and <em>in vivo</em> standard genotoxicity assays concludes to no mutagenic or clastogenic potential of agomelatine.</p><p>&nbsp;</p><p>In carcinogenicity studies agomelatine induced an increase in the incidence of liver tumours in the rat and the mouse<strong>, </strong>at a dose at least 110-fold higher than the therapeutic dose. Liver tumours are most likely related to enzyme induction specific to rodents. The frequency of benign mammary fibroadenomas observed in the rat was increased with high exposures (60-fold the exposure at the therapeutic dose) but remains in the range of that of controls.</p><p>&nbsp;</p><p>Safety pharmacology studies showed no effect of agomelatine on hERG (human Ether &agrave;-go-go Related Gene) current or on dog Purkinje cells action potential. Agomelatine did not show proconvulsive properties at ip doses up to 128 mg/kg in mice and rats.</p><p>&nbsp;</p><p>No effect of agomelatine on juvenile animals behavioural performances, visual and reproductive function were observed. There were mild non dose dependent decreases in body weight related to the pharmacological properties and some minor effects on male reproductive tract without any impairment on reproductive performances.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>&nbsp;</p><p>Lactose monohydrate</p><p>Maize starch</p><p>Povidone (K30)</p><p>Sodium starch glycolate type A</p><p>Stearic acid</p><p>Magnesium stearate</p><p>Silica, colloidal anhydrous</p><p>&nbsp;</p><p><u>Film-coating</u></p><p>&nbsp;</p><p>Hypromellose</p><p>Yellow iron oxide (E172)</p><p>Glycerol</p><p>Macrogol (6000)</p><p>Magnesium stearate</p><p>Titanium dioxide (E171)</p><p>&nbsp;</p><p>Printing ink containing shellac, propylene glycol and indigo carmine aluminium lake (E132).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special storage conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium/PVC blister packed in cardboard boxes.</p><p>Calendar packs containing 14, 28, 56, 84 and 98 film-coated tablets.</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Les Laboratoires Servier
50, rue Carnot
92284 Suresnes cedex
France
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05.2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>